Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss

Regeneron Pharmaceuticals will make its newly approved gene therapy for a rare, genetic form of hearing loss available for free in the U.S. The company hasn't yet decided how much it will charge in other countries, Regeneron CEO Leonard Schleifer told CNBC on Friday."We haven't set a price yet, but they should pay t…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.